BioCentury
ARTICLE | Emerging Company Profile

Kesios: Reactivating apoptosis

Kesios targeting tumor-specific NF-kappa B signaling for safer MM treatment

October 20, 2014 7:00 AM UTC

Kesios Therapeutics Ltd. is targeting a downstream component of the NF-kappa B signaling pathway that is overexpressed in multiple myeloma cells with the aim of providing efficacy similar to other MM therapies, but with a safer side effect profile.

Despite NF-kB's well-known role in immune responses, inflammation and cell survival - and certain cancers' propensity to harness the mechanism - the pathway has been difficult to target directly because of its ubiquitous nature and role in regulating both healthy and aberrant cells...